AbbVie Inc (ABBV)vsCarlsmed, Inc. (CARL)
ABBV
AbbVie Inc
$261.74
+1.79%
HEALTHCARE · Cap: $454.36B
CARL
Carlsmed, Inc.
$14.73
-0.20%
HEALTHCARE · Cap: $402.17M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 101624% more annual revenue ($64.39B vs $63.30M). ABBV leads profitability with a 9.8% profit margin vs -57.4%. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
CARL
Avoid30
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-69.4%
Fair Value
$151.82
Current Price
$261.74
$109.92 premium
Intrinsic value data unavailable for CARL.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Revenue surging 56.7% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
0.0% earnings growth
Distress zone — elevated risk
Smaller company, higher risk/reward
ROE of -43.1% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.52 suggests the stock is reasonably priced for its growth.
Bull Case : CARL
The strongest argument for CARL centers on Revenue Growth, Debt/Equity. Revenue growth of 56.7% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 72.0x leaves little room for execution misses.
Bear Case : CARL
The primary concerns for CARL are EPS Growth, Altman Z-Score, Market Cap.
Key Dynamics to Monitor
ABBV profiles as a value stock while CARL is a hypergrowth play — different risk/reward profiles.
CARL is growing revenue faster at 56.7% — sustainability is the question.
ABBV generates stronger free cash flow (3.2B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (73/100 vs 30/100) and 10.2% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Carlsmed, Inc.
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Carlsmed, Inc. develops and operates a surgical platform for the treatment of complex adult spinal deformities that enables surgeons to harness clinical intelligence, advanced image recognition, and 3D printing technologies. The company is headquartered in Carlsbad, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?